CYP1A1, mEH, and GSTM1 Polymophisms and Risk of Oral and Pharyngeal Cancer: A Spanish Case-Control Study
Table 3
Risks for the different polymorphisms broken down by
smoking categories.
Genetic polymorphism
Cases
Controls
OR crude
OR adjusted
Light/moderate
smokers (≤35 pack-years)
CYP1A1
No mutated
28
41
1.00
1.00
Mutated
1
2
0.76 (0.06–8.90)
1.12 (0.09–13.94)
mEH (139)
His/His
20
58
1.00
1,00
His/Arg
8
24
1.06 (0.40–2.78)
1.08 (0.37–3.13)
Arg/arg
1
1
1.91 (0.11–33.10)
2.82 (0.15–52.41)
GSTM1
Present
17
43
1.00
1.00
Absent
12
40
0.74 (0.31–1.76)
0.88 (0.34–2.34)
Heavy smokers
(>35 pack-years)
CYP1A1
No mutated
23
62
1.00
1.00
Mutated
0
1
—
—
mEH (139)
His/His
43
30
1.00
1.00
His/Arg
17
17
0.94 (0.39–2.26)
0.68 (0.25–1.86)
Arg/arg
3
0
—
—
GSTM1
Present
28
25
1.00
1.00
Absent
35
22
1.50 (0.67–1.33)
1.40 (0.57–3.43)
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.
